Skip to main content

Idorsia Stock Forecast, Price & News

-1.04 (-3.99 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume263 shs
Average Volume1,347 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IDRSF News and Ratings via Email

Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter.

Idorsia logo

About Idorsia

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.


See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Phone41 58 844 10 10
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.54 out of 5 stars

Medical Sector

1498th out of 2,044 stocks

Biotechnology Industry

82nd out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Idorsia (OTCMKTS:IDRSF) Frequently Asked Questions

Is Idorsia a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Idorsia stock.
View analyst ratings for Idorsia
or view top-rated stocks.

What stocks does MarketBeat like better than Idorsia?

Wall Street analysts have given Idorsia a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Idorsia wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Idorsia's stock been impacted by COVID-19 (Coronavirus)?

Idorsia's stock was trading at $25.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IDRSF stock has decreased by 1.0% and is now trading at $25.00.
View which stocks have been most impacted by COVID-19

Who are Idorsia's key executives?

Idorsia's management team includes the following people:
  • Mr. Jean-Paul Clozel, CEO & Director (Age 66)
  • Mr. André C. Muller, Exec. VP & CFO (Age 58)
  • Dr. Martine Clozel, Exec. VP & Chief Scientific Officer (Age 66)
  • Mr. Andrew C. Weiss, Sr. VP and Head of Investor Relations & Corp. Communications (Age 53)
  • Mr. Oliver Peinelt, Sr. VP & Group Gen. Counsel (Age 51)
  • Mr. Alexander Khatuntsev, Sr. VP & Head of HR (Age 43)
  • Dr. Guy Braunstein, Exec. VP & Head of Global Clinical Devel. (Age 65)
  • Mr. Simon Jose, Exec. VP & Chief Commercial Officer
  • Mr. Olivier Lambert, Sr. VP & Head of Pharmaceutical Devel. (Age 55)
  • Mr. Markus A. Riederer, Sr. VP & Head of Drug Discovery Biology (Age 59)

Who are some of Idorsia's key competitors?

What is Idorsia's stock symbol?

Idorsia trades on the OTCMKTS under the ticker symbol "IDRSF."

How do I buy shares of Idorsia?

Shares of IDRSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Idorsia's stock price today?

One share of IDRSF stock can currently be purchased for approximately $25.00.

What is Idorsia's official website?

The official website for Idorsia is

How can I contact Idorsia?

The company can be reached via phone at 41 58 844 10 10.

This page was last updated on 5/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.